Pfizer opens new precision drug center; Fate strikes pact for NK cancer drug development;

@FierceBiotech: Biopharma's 10 highest-paid heads of R&D. Feature | Follow @FierceBiotech

@JohnCFierce: $CELG chief Bob Hugin isn't done betting on 'binary' biotech deals--"we're going to go after them at the right time." Report | Follow @JohnCFierce

@DamianFierce: Here's the $CELG + $RCPT release. PR/Story | Follow @DamianFierce

> Pfizer ($PFE) debuted its Center of Excellence in Precision Medicine in Santiago, Chile, last week, bulking up in Latin America, which is not exactly a hot spot for pharma industry R&D. Story

> Fate Therapeutics ($FATE) has struck a deal to collaborate with the University of Minnesota for the development of natural killer (NK) cell-based cancer immunotherapeutics. Release

Medical Device News

@FierceMedDev: Swedish biotech ropes in $11M for automated HIV testing device. FierceDiagnostics item | Follow @FierceMedDev

@VarunSaxena2: ICYMI: India moving closer to implementing price controls on medical devices. Story | Follow @VarunSaxena2

@EmilyWFierce: JAMA: Noninvasive prenatal tests can pinpoint cancer in mothers. Story | Follow @EmilyWFierce

> U.K. researchers develop noninvasive, infrared-based blood glucose monitor, license it to startup. More

> Breakout Dx player Theranos keys into Medicaid with latest deal in managed care. Article

Pharma News

@FiercePharma: Almac's launch of Singapore APAC HQ also eyes regional growth of small biotechs. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: Why did FDA ban Emcure India plant? Recall of drugs manufactured for Teva may provide a clue. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: AZ's Iressa gets back in the game with first-line FDA approval in lung cancer. Report | Follow @CarlyHFierce

> J&J set to reopen McNeil plant amid consumer biz overhaul. Article

> Sanofi CEO revamps operations, tapping chiefs for 3 new units. More

Pharma Marketing News

> J&J chief touts $1B-plus prospects for coming psoriasis med guselkumab. More

> Dr. Reddy's spruces up corporate branding for U.S. marketing assault. Item

> Roche's atezo lines up PD-L1 data for forthcoming battle with Keytruda, Opdivo. Story

> Two agency giants duke it out for GlaxoSmithKline $900M media account. Report

> Programmatic's the latest word for targeting drug pitches to the right docs. Article

Biotech Research News

> Peptide shells provide a targeted cancer drug delivery system. Item

> Caspase-1 molecule highlighted as key player in regulating vascular ischemia. More

> Johns Hopkins team points to a new therapeutic approach to hearing loss. Report

> Penn study confirms a link between male infertility and genetic mutations. Story

> Nonviral gene therapy shrinks brain tumors in rats. Article

Diagnostics News

> Merck invests $6M in microbial diagnostics specialist OpGen. Report

> Qiagen scores FDA approval for lung cancer companion Dx. News

> Xagenic reels in $15M for point-of-care testing system. Story

> Natera joins forces with University College London for lung cancer study. Article

> CombiMatrix coasts toward growth with renewed sales push. Editor's corner

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

NYC’s outstanding talent and funding, the city is rich with life science real estate offerings across the five boroughs.

Sutro Biopharma’s lead antibody-drug conjugate shrank tumors in 13% of patients with ovarian cancer who had tried a median of six other treatments.

Immuno-oncology biotech Silverback Therapeutics has more than doubled its original IPO hopes.